The FDA has approved the oral SERD elacestrant to treat certain patients with estrogen receptor-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved elacestrant (Orserdu) for the treatment of men and...
The FDA granted accelerated approval to the BTK inhibitor pirtobrutinib for the treatment of mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca) for the treatment...
Pembrolizumab was approved to treat some patients with lung cancer after surgery and chemotherapy. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the adjuvant treatment of stage IB, II, or...
The FDA approved tucatinib for certain patients with unresectable or metastatic colorectal cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab for the treatment...
The FDA approved zanubrutinib, a second-generation Bruton’s tyrosine kinase inhibitor. The U.S. Food and Drug Administration (FDA) has approved zanubrutinib (Brukinsa) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ...
The FDA granted accelerated approval to mosunetuzumab-axgb, the first bispecific antibody approved to treat a form of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mosunetuzumab-axgb (Lunsumio) for...
The FDA approved the adenovirus-based gene therapy nadofaragene firadenovec for the treatment of localized bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nadofaragene firadenovec (Adstiladrin) for the treatment of adult patients...
A second inhibitor of the difficult-to-target KRAS protein was approved to treat certain lung cancers. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to adagrasib (Krazati) for adult patients with locally...
The FDA approved the PD-L1 inhibitor atezolizumab to treat alveolar soft part sarcoma The U.S. Food and Drug Administration has approved atezolizumab (Tecentriq) for the treatment of patients 2 years of age or older...
A second inhibitor of mutant IDH1 was approved to treat certain blood cancers. The U.S. Food and Drug Administration (FDA) has approved olutasidenib (Rezlidhia) for patients with relapsed or refractory acute myeloid leukemia (AML)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 50,000 members worldwide drive progress against cancer.
Donate Now